feedback

Course Director

Mollie Moran, APRN-CNP, AOCNP
Mollie Moran, APRN-CNP, AOCNP

The James Cancer Hospital at The Ohio State University Medical Center
Columbus, Ohio

Faculty

Amy Goodrich
Amy Goodrich, NP

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Pia Nierman
Pia Nierman, BSN

National Institutes of Health
Bethesda, Maryland

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CNE / CE
Credit Amount:1.5 Credits
Release Date:2019-May-16
Expiration Date:2020-May-15
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, based on a recent live symposium held during the Oncology Nursing Society’s (ONS) 44th Annual Congress, a panel of expert nurse faculty use a MasterClass/case-forum design to offer an in-depth review of BTK inhibitors, their therapeutic applications in B-cell malignancies, and the core nurse-focused practice issues that are central to the further integration of BTK inhibitors into treatment plans for patients with cancers such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), among other B-cell disorders.

Upon completion of this activity, participants will be able to:
  • Summarize updated safety and efficacy evidence about first- and second-generation BTK inhibitors in the management of B-cell cancer
  • Cite dosing considerations, administration strategies, and treatment schedules of BTK inhibitors for the management of newly diagnosed or refractory/relapsed B-cell cancer
  • Educate patients about the varying side effect profiles, efficacy outcomes, and potential for treatment resistance associated with the use of BTK inhibitors for B-cell cancer
  • Manage side effect and adherence considerations in patients with B-cell cancer treated with BTK inhibitors

Target Audience

This activity has been designed to meet the educational needs of oncology nurses and other clinicians involved in the management of patients with B-cell malignancies.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CNE/CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CNE/CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: May 16, 2019 - May 15, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CNE/CE activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CNE/CE activity during the past 12 months.

Course Director and Moderator

Mollie Moran, APRN-CNP, AOCNP
Oncology Nurse Practitioner
The James Cancer Hospital at The Ohio State University Medical Center
Columbus, Ohio

Mollie Moran, APRN-CNP, AOCNP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie.

Mollie Moran, APRN-CNP, AOCNP, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: ibrutinib, acalabrutinib, zanubrutinib as single-agents or combinations in different B-cell cancer settings.

Faculty

Amy Goodrich, NP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Amy Goodrich, NP, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Gilead Sciences, Inc.; Mylan N.V.; and Sandoz AG.

Amy Goodrich, NP, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: ibrutinib, acalabrutinib, zanubrutinib as single-agents or combinations in different B-cell cancer settings.

Pia Nierman, BSN
National Institutes of Health
Bethesda, Maryland

Pia Nierman, BSN, has no financial interests/relationships or affiliations in relation to this activity.

Pia Nierman, BSN, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: ibrutinib, acalabrutinib, zanubrutinib as single-agents or combinations in different B-cell cancer settings.

Content Reviewers

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Janice Trainor-Tellier, MSN, RN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Laura Healy
PVI, PeerView Institute for Medical Education

Laura Healy has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CNE/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.5 contact hour(s).

Nurse Practitioners

This activity is approved for 1.5 contact hour(s) of continuing education (which includes 1.5 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19043696. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Providership


This CNE/CE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CNE/CE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.